Evofem Q3 preliminary net product sales $5.0-5.2M; loss from ops down >80% YoY

Evofem Biosciences, Inc.

2023-Q3 EPS reported $0.09 vs consensus -$0.06 ▲ beat (+247.1%)

Phexxi net product sales expected $5.0-5.2M for Q3 2023; on track for third consecutive year of growth.
Selling/marketing expenses >75% lower, total operating expenses >65% lower versus Q3 2022.
Loss from operations reduced >80% YoY; expects lowest quarterly operating loss to date.
Fourth amendment to convertible notes: may repurchase $25M notes for as little as $14M; initial $1M paid.
Generic competitor amended ANDA; will not seek FDA approval until Phexxi patents expire in 2033.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evofem Biosciences, Inc. reported the third quarter of 2023 results: revenue $5.0 to $5.2 million.

Period: the third quarter of 2023
Revenue: $5.0 to $5.2 million
Result: preliminary results

Exact text from the filing

gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives. ● Phexxi net product sales expected to be $5.0 to $5.2 million for the third quarter of 2023. ● Evofem remains on track to deliver its third consecutive year of net product sales growth. ● Selling and marketing expenses were

View on SEC.gov

Browse all earnings releases →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-038044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.